Medical Health & Life Science Research News

Research focused on the obesity - pipeline review, H1 2018

Medical Market Research

Obesity - Pipeline Review, H1 2018 is latest pipeline review released by HTF MI to provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, root cause analysis ,mechanism of action (MoA), route of administration (RoA) and molecule type.

If you are want to study the Obesity or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players.

If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs. 

Get Access to Sample PDF @:…pipeline-review-4 Make an Inquiry about this news

Obesity is defined as having an excessive amount of body fat.

Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure.

The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Key Players included in the research study are Abeome Corp, Adocia SAS, Aegis Therapeutics LLC, Amgen Inc, Antag Therapeutics ApS, Aoxing Pharmaceutical Company Inc, Arrowhead Pharmaceuticals Inc, AstraZeneca Plc, Athersys Inc, Auris Medical Holding AG, Bial - Portela & Ca SA, Biophytis SA, BioRestorative Therapies Inc, Biozeus, Boehringer Ingelheim GmbH, Braasch Biotech LLC, C3J Therapeutics Inc, Callitas Therapeutics Inc, Carmot Therapeutics Inc, Celon Pharma SA, Chong Kun Dang Pharmaceutical Corp, CohBar Inc, CoMentis Inc, Corcept Therapeutics Inc, Daiichi Sankyo Co Ltd, DiscoveryBiomed Inc, Eisai Co Ltd, Eli Lilly and Co, Eternygen GmbH, Evotec AG, FibroGen Inc, Genmedica Therapeutics SL, Gila Therapeutics Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Glucox Biotech AB, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, Hyundai Pharmaceutical Co Ltd, Immungenetics AG, Intarcia Therapeutics Inc, Ionis Pharmaceuticals Inc, Johnson & Johnson, Juno Therapeutics Inc, Kissei Pharmaceutical Co Ltd, Lead Discovery Center GmbH, Leading BioSciences Inc, Magnus Life Ltd, MedImmune LLC, Merck & Co Inc, Naia Ltd, NeuroNano Pharma Inc, NGM Biopharmaceuticals Inc, NIBEC, Nordic Bioscience A/S, Novartis AG, Novo Nordisk AS, ObeTherapy Biotechnology, Omeros Corp, OPKO Biologics Ltd, OPKO Health Inc, Oramed Pharmaceuticals Inc, Palatin Technologies Inc, Peptron Inc, Pfizer Inc, PharmaIN Corp, Poxel SA, ProMetic Life Sciences Inc, Regeneron Pharmaceuticals Inc, Renova Therapeutics Inc, Reviva Pharmaceuticals Inc, Saniona AB, Sanofi, Seres Therapeutics Inc, Shionogi & Co Ltd, Sinil Pharmaceutical Co Ltd, SJT Molecular Research SL, Takeda Pharmaceutical Co Ltd, Toray Industries Inc, Vicore Pharma AB, Viking Therapeutics Inc, Vivus Inc, WhanIn Pharmaceutical Co Ltd, XL-protein GmbH, Yuhan Corp, Yuyu Pharma Inc, Zafgen Inc & Zealand Pharma AS. 

Make inquiry@…pipeline-review-4 Make an Inquiry about this news 

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. 

Obesity pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision making capabilities and helps to create effective marketing strategies to gain competitive advantage in health care and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real time basis. 

Access this research report @…mp;report=1197577 Make an Inquiry about this news 

Extracts of Chapters from Obesity - Pipeline Review, H1 2018 
Chapter 1 , to describe the definition , overview and Therapeutics Development of Obesity. 
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes. 
Chapter3, Therapeutics Assessment of Obesity by Target, Mechanism of Action, Route of Administration and by Molecule Type. 
Chapter4, to display company profile involved in Therapeutics Development. 
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Obesity. 
Chapter 6,7, to describe Obesity Appendix, Methodology ,Coverage ,Secondary Research ,Primary Research ,Expert Panel Validation and Contact Us. 

Objective of this study 

- To provides a snapshot of the global therapeutic landscape of Obesity. 
- To reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Obesity therapeutics and enlists all their major and minor projects. 
- The pipeline guide evaluates Obesity therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. 
- The guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity 

Reasons to access 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
- Find and recognize significant and varied types of therapeutics under development for Obesity. 
- Classify potential new clients or partners in the target demographic. 
- Develop tactical initiatives by understanding the focus areas of leading companies. 
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. 
- Formulate corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics. 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Read Detailed Index of full Research Study at @…pipeline-review-4 Make an Inquiry about this news 

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany about: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information:

Make an Inquiry about this report HERE!